清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Targeting the LPI / GPR55 Axis in MAFLD and MASH : Novel Insights, Therapeutic Strategies and Future Directions

作者
Jerome Lian,Ricky R. Lareu,Mohan Patil,Marco Falasca
出处
期刊:Liver International [Wiley]
卷期号:46 (4): e70576-e70576 被引量:5
标识
DOI:10.1111/liv.70576
摘要

Metabolic dysfunction-associated fatty liver disease (MAFLD), recently redefined from non-alcoholic fatty liver disease (NAFLD), highlights the central role of metabolic dysfunction in its pathophysiology. The L-α-lysophosphatidylinositol/G protein-coupled receptor 55 (LPI/GPR55) axis, an element of the endocannabinoidome, has emerged as a key driver behind liver disease progression, leading to the progression of metabolic dysfunction associated steatohepatitis (MASH). Implicated in hepatic lipid accumulation, inflammation and fibrosis, this axis has detrimental effects in hepatocytes, Kupffer cells and hepatic stellate cells. Furthermore, recent evidence suggests that this axis induces de novo lipogenesis, promoting pro-inflammatory cytokine production, leading to fibrosis and the transition toward a steatotic liver. The enzyme membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) modulates this axis by acylation of LPI, exacerbating hepatic steatosis and insulin resistance. Until recently, no pharmacologic treatments were approved for MAFLD. However, resmetirom received FDA approval in March 2024 for the treatment of MASH, and semaglutide (Wegovy) was granted accelerated FDA approval in August 2025 for MASH with moderate-to-advanced fibrosis. Additional agents such as tirzepatide and retatrutide remain in late-stage clinical development. We propose that targeting the endocannabinoidome, specifically the LPI/GPR55 axis, represents a promising therapeutic strategy for liver disease. Previous attempts to target GPR55 therapeutically have involved small-molecule agonists and phytocannabinoids with antagonistic activity. However, progress remains limited due to the context-specific roles of GPR55 across different tissues and signalling pathways. As such, future strategies involving the LPI/GPR55 axis must focus on hepatic-specific GPR55 modulation using selective ligands and advanced delivery systems, mitigating off-target effects. This review elucidates the mechanistic role of the LPI/GPR55 axis, combining the role of MBOAT7 in the pathophysiology of metabolic-associated liver disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
alex发布了新的文献求助10
4秒前
我不是哪吒完成签到 ,获得积分10
4秒前
冷傲的月饼完成签到,获得积分10
5秒前
乐观的星月完成签到 ,获得积分0
7秒前
SCINEXUS完成签到,获得积分0
8秒前
龙弟弟完成签到 ,获得积分10
8秒前
ooouiia完成签到 ,获得积分10
15秒前
科研通AI65的应助被冲冲冲采纳,获得10
16秒前
Beyond095完成签到 ,获得积分10
18秒前
芍药完成签到 ,获得积分10
22秒前
逍遥子完成签到,获得积分10
27秒前
申燕婷完成签到 ,获得积分10
28秒前
孤独晓绿完成签到,获得积分10
29秒前
高高的夏波完成签到,获得积分10
31秒前
John的应助被一an颜采纳,获得10
31秒前
32秒前
34秒前
Aboo完成签到,获得积分10
36秒前
大可完成签到 ,获得积分10
38秒前
冲冲冲发布了新的文献求助10
39秒前
43秒前
GLUUUUUE完成签到 ,获得积分10
43秒前
叶问夏完成签到 ,获得积分10
48秒前
尐吜渔发布了新的文献求助10
51秒前
53秒前
科研通AI6.2的应助被尐吜渔采纳,获得10
59秒前
善良的梦桃完成签到,获得积分10
1分钟前
楚楚完成签到 ,获得积分10
1分钟前
闫小昊完成签到,获得积分10
1分钟前
Maestro_S的应助被博修采纳,获得100
1分钟前
魔幻荧完成签到,获得积分10
1分钟前
张博完成签到 ,获得积分10
1分钟前
LYH完成签到,获得积分10
1分钟前
J_Xu完成签到 ,获得积分10
1分钟前
七叶花开完成签到,获得积分10
1分钟前
SunJay完成签到 ,获得积分10
1分钟前
复杂以旋完成签到,获得积分10
1分钟前
心无杂念完成签到 ,获得积分10
1分钟前
Shicheng发布了新的文献求助10
1分钟前
忧虑的静柏完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780536
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697